Literature DB >> 16249124

Catatonia induced by levetiracetam.

Marie-Josée Chouinard1, Dang-Khoa Nguyen, Jean-François Clément, Marie-Andrée Bruneau.   

Abstract

Levetiracetam (Keppra) is a novel antiepileptic drug approved as adjunctive treatment for adults with partial onset seizures. Although the drug is generally well tolerated, behavioral side effects have been reported in variable frequency. Most behavioral problems are mild in nature (agitation, hostility, anxiety, emotional lability, apathy, depression) and quickly resolve with discontinuation of medication. However, serious psychiatric adverse events may also occur with rare cases of psychosis and suicidal behavior. We report here the case of a 43-year-old woman who developed symptoms compatible with catatonia after being exposed to levetiracetam for the treatment of epilepsy. To our knowledge, it is the first reported case of catatonia induced by levetiracetam. We review the difficulties that may be encountered in the differential diagnosis of medical catatonia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249124     DOI: 10.1016/j.yebeh.2005.04.016

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

1.  Commentary.

Authors:  Jurjen J van Zwieten; Jan N M Schieveld
Journal:  J Neurosci Rural Pract       Date:  2014-07

2.  Commentary.

Authors:  Roshan Bhad
Journal:  J Neurosci Rural Pract       Date:  2014-07

Review 3.  A clinical review of the treatment of catatonia.

Authors:  Pascal Sienaert; Dirk M Dhossche; Davy Vancampfort; Marc De Hert; Gábor Gazdag
Journal:  Front Psychiatry       Date:  2014-12-09       Impact factor: 4.157

4.  Catatonia in a patient with bipolar disorder type I.

Authors:  Ather Muneer
Journal:  J Neurosci Rural Pract       Date:  2014-07

5.  Commentary.

Authors:  Walter Jaimes-Albornoz
Journal:  J Neurosci Rural Pract       Date:  2014-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.